Jeff Cislini, General Counsel at Revolution Medicines, Inc. (NASDAQ:RVMD), has recently sold a portion of his holdings in the company. According to a recent SEC filing, Cislini sold 2,406 shares of common stock on January 21, 2025, at a price of $40.50 per share, totaling approximately $97,443. The sale was executed near the current trading price of $40.92 in the $7.56 billion market cap company. InvestingPro analysis indicates the stock is currently in oversold territory, with strong balance sheet metrics showing more cash than debt.
The transaction was executed under a 10b5-1 trading plan, which Cislini adopted on March 20, 2024. Following this sale, Cislini retains ownership of 39,222 shares, which includes 36,204 restricted stock units. According to InvestingPro, which offers comprehensive analysis of 1,400+ stocks including RVMD, the company maintains a healthy current ratio of 14.24, indicating strong short-term financial stability. Subscribers can access 5 additional ProTips and detailed financial metrics in the Pro Research Report.
In other recent news, Revolution Medicines has seen significant developments. The company completed an upsized public offering, raising approximately $862.5 million, which led Needham to adjust its stock price target for Revolution to $62 from $68, while maintaining a Buy rating. Guggenheim also maintained its Buy rating and increased the price target to $87, following a major clinical data update on Revolution's RAS inhibitor pipeline.
Revolution Medicines also initiated a public offering of common stock valued at up to $600 million. The company's RAS inhibitor pipeline, including RMC-6236 and RMC-6291, has demonstrated promising safety and efficacy in various cancer treatments. Revolution Medicines reported significant updates on its clinical trials for RAS-addicted cancers, further underpinning the firm's continued recommendation to buy Revolution shares.
The company's RMC-6236-001 study demonstrated positive safety and tolerability in pancreatic ductal adenocarcinoma treatment, and the combination of RMC-6236 with pembrolizumab showed potential, as did the combination of RMC-6236 with RMC-6291 in treating advanced RAS G12C mutant solid tumors. These are among the recent developments in Revolution Medicines' ongoing clinical programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.